How could patient reported outcomes improve patient management in chronic myeloid leukemia?

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Kris MG, Benowitz SI, Adams S, et al. Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2010 Dec 20;28(36):5327–5347.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011 Apr 6;103(7):553–561.
   PubMedGoogle Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 8;122(6):872–884.
   PubMed Web of Science ®Google Scholar
• Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009 May 28;113(22):5401–5411.
   PubMed Web of Science ®Google Scholar
• Marin D. Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2012;2012:115–121.
   PubMedGoogle Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 7;355(23):2408–2417.
   PubMed Web of Science ®Google Scholar
• Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012 Oct;26(10):2197–2203.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012 Feb 2;119(5):1123–1129.
   PubMed Web of Science ®Google Scholar
• Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol. 2003 Jun 1;21(11):2138–2146.
   PubMed Web of Science ®Google Scholar
• Efficace F, Rosti G, Aaronson N, et al. Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica. 2014 Apr;99(4):788–793.
   PubMed Web of Science ®Google Scholar
• Ganna A, Ingelsson E. 5-year mortality predictors in 498,103 UK Biobank participants: a prospective population-based study. Lancet. 2015 Aug 8;386(9993):533–540.
   PubMed Web of Science ®Google Scholar
• Hauser CA, Stockler MR, Tattersall MH. Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer. 2006 Oct;14(10):999–1011.
   PubMed Web of Science ®Google Scholar
• Singh JA, Nelson DB, Fink HA, et al. Health-related quality of life predicts future health care utilization and mortality in veterans with self-reported physician-diagnosed arthritis: the veterans arthritis quality of life study. Semin Arthritis Rheum. 2005 Apr;34(5):755–765.
   PubMed Web of Science ®Google Scholar
• Fan VS, Curtis JR, Tu SP, et al.; Ambulatory Care Quality Improvement Project Investigators. Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases. Chest. 2002 Aug;122(2):429–436.
   PubMed Web of Science ®Google Scholar
• Lopes AA, Lantz B, Morgenstern H, et al. Associations of self-reported physical activity types and levels with quality of life, depression symptoms, and mortality in hemodialysis patients: the DOPPS. Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1702–1712.
   PubMed Web of Science ®Google Scholar
• Cunningham WE, Crystal S, Bozzette S, et al. The association of health-related quality of life with survival among persons with HIV infection in the United States. J Gen Intern Med. 2005 Jan;20(1):21–27.
   PubMed Web of Science ®Google Scholar
• Dorr DA, Jones SS, Burns L, et al. Use of health-related, quality-of-life metrics to predict mortality and hospitalizations in community-dwelling seniors. J Am Geriatr Soc. 2006 Apr;54(4):667–673.
   PubMed Web of Science ®Google Scholar
• Basch E, Geoghegan C, Coons SJ, et al. Patient-reported outcomes in cancer drug development and US regulatory review: perspectives from industry, the Food and Drug Administration, and the patient. JAMA Oncol. 2015 Jun;1(3):375–379.
   PubMed Web of Science ®Google Scholar
• Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993 Mar;11(3):570–579.
   PubMed Web of Science ®Google Scholar
• Niezgoda HE, Pater JL. A validation study of the domains of the core EORTC quality of life questionnaire. Qual Life Res. 1993 Oct;2(5):319–325.
   PubMed Web of Science ®Google Scholar
• Detmar SB, Muller MJ, Schornagel JH, et al. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. Jama. 2002 Dec 18;288(23):3027–3034. Erratum in: JAMA. 2003 Feb 26;289(8):987.
   PubMed Web of Science ®Google Scholar
• Pidala J, Anasetti C, Jim H. Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention. Br J Haematol. 2010 Feb;148(3):373–385.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365–376.
   PubMed Web of Science ®Google Scholar
• Buckstein R, Wells RA, Zhu N, et al. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. Br J Haematol. 2016 Jul;174(1):88–101.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Brandenburg NA, Muus P, et al. Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with low- or intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial. Leuk Res. 2013 Mar;37(3):259–265.
   PubMed Web of Science ®Google Scholar
• Wisløff F, Hjorth M. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol. 1997 Apr;97(1):29–37.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Richardson PG, Sonneveld P, et al. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol. 2008 Nov;143(4):511–519.
   PubMed Web of Science ®Google Scholar
• King CR, Haberman M, Berry DL, et al. Quality of life and the cancer experience: the state-of-the-knowledge. Oncol Nurs Forum. 1997 Jan-Feb;24(1):27–41.
   PubMedGoogle Scholar
• Wisløff F, Eika S, Hippe E, et al. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol. 1996 Mar;92(3):604–613.
   PubMed Web of Science ®Google Scholar
• Kvam AK, Fayers P, Hjermstad M, et al. Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. Eur J Haematol. 2009 Oct;83(4):279–289.
   PubMed Web of Science ®Google Scholar
• Dubois D, Dhawan R, van de Velde H, et al. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol. 2006 Feb 20;24(6):976–982.
   PubMed Web of Science ®Google Scholar
• Alibhai SM, O’Neill S, Fisher-Schlombs K, et al. A clinical trial of supervised exercise for adult inpatients with acute myeloid leukemia (AML) undergoing induction chemotherapy. Leuk Res. 2012 Oct;36(10):1255–1261.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111–121.
   PubMed Web of Science ®Google Scholar
• Deisseroth A, Kaminskas E, Grillo J, et al. U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res. 2012 Jun 15;18(12):3212–3217.
   PubMed Web of Science ®Google Scholar
• Else M, Smith AG, Cocks K, et al. Patients’ experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial. Br J Haematol. 2008 Dec;143(5):690–697.
   PubMed Web of Science ®Google Scholar
• de Wreede LC, Watson M, van Os M, et al. Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study. Am J Hematol. 2014 Feb;89(2):174–180.
   PubMed Web of Science ®Google Scholar
• Jacobsen PB, Le-Rademacher J, Jim H, et al. Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. Biol Blood Marrow Transplant. 2014 Oct;20(10):1530–1536. DOI:10.1016/j.bbmt.2014.05.027
   PubMed Web of Science ®Google Scholar
• Wa W, Le-Rademacher J, Syrjala KL, et al. Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902). Cancer. 2016 Jan 1;122(1):91–98.
   PubMed Web of Science ®Google Scholar
• Abel GA, Albelda R, Khera N, et al. Financial hardship and patient-reported outcomes after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016 May 13;pii: S1083-8791(16)30080-5. DOI:10.1016/j.bbmt.2016.05.008
   PubMed Web of Science ®Google Scholar
• Larson RA. Is there a best TKI for chronic phase CML? Blood. 2015 Nov 19;126(21):2370–2375.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010 Nov;11(11):1029–1035.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016 May;30(5):1044–1054.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic Myeloid leukemia patients trial. J Clin Oncol. 2016 Jul 10;34(20):2333–2340.
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011 Oct 27;118(17):4554–4560.
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010 May 10;28(14):2381–2388.
   PubMed Web of Science ®Google Scholar
• Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011 Apr 7;117(14):3733–3736.
   PubMed Web of Science ®Google Scholar
• Kekäle M, Talvensaari K, Koskenvesa P, et al. Chronic myeloid leukemia patients’ adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians. Patient Prefer Adherence. 2014;8:1619–1627.
   PubMed Web of Science ®Google Scholar
• Yood MU, Oliveria SA, Cziraky M, et al. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin. 2012 Feb;28(2):213–219.
   PubMed Web of Science ®Google Scholar
• Efficace F, Cardoni A, Cottone F, et al. Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review. Leuk Res. 2013 Feb;37(2):206–213.
   PubMed Web of Science ®Google Scholar
• Guérin A, Chen L, Ionescu-Ittu R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin. 2014 Nov;30(11):2317–2328.
   PubMed Web of Science ®Google Scholar
• Labeit AM, Copland M, Cork LM, et al. Assessment of quality of life in the NRCI Spirit 2 study comparing imatinib and dasatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. Blood. 2015;126:abstract 4024.
   Web of Science ®Google Scholar
• Trask PC, Cella D, Besson N, et al. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res. 2012 Apr;36(4):438–442.
   PubMed Web of Science ®Google Scholar
• Phillips KM, Pinilla-Ibarz J, Sotomayor E, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013 Apr;21(4):1097–1103.
   PubMed Web of Science ®Google Scholar
• Hirji I, Gupta S, Goren A, et al. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective. Health Qual Life Outcomes. 2013;11:167.
   PubMed Web of Science ®Google Scholar
• Lutge I, Pfirrmann M, Stalljann I, et al. Health-related quality of life in CML patients under nilotinib first-line treatment: result of a German sub-study within the ENEST1st trial. Haematologica. 2015;100(suppl 1):abstract 233.
   Google Scholar
• Cella D, Webster K, Du H, et al. Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy – Leukemia (FACT-Leu) questionnaire. Value Health. 2012 Dec;15(8):1051–1058.
   PubMed Web of Science ®Google Scholar
• Cella D, Nowinski CJ, Frankfurt O. The impact of symptom burden on patient quality of life in chronic myeloid leukemia. Oncology. 2014;87:133–147.
   PubMed Web of Science ®Google Scholar
• Williams LA, Garcia Gonzalez AG, Ault P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013 Aug 1;122(5):641–647.
   PubMed Web of Science ®Google Scholar
• Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89(7):1634–1646.
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, et al. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res. 2014 Apr;23(3):825–836.
   PubMed Web of Science ®Google Scholar
• Kotronoulas G, Kearney N, Maguire R, et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol. 2014 May 10;32(14):1480–1501.
   PubMed Web of Science ®Google Scholar
• Hughes T, White D. Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematology Am Soc Hematol Educ Program. 2013;168–175. DOI:10.1182/asheducation-2013.1.168
   PubMed Web of Science ®Google Scholar
• Kirkizlar O, Eskazan AE. Adverse events of tyrosine kinase inhibitors and their impact on quality of life in patients with chronic myeloid leukemia. Expert Rev Qual Life Cancer Care. 2016;1(5):353–359.
   Google Scholar